CPA
ELVN icon

Capital Performance Advisors’s Enliven Therapeutics ELVN Stock Holding History

Capital Performance Advisors’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-32
Closed -$817 – 922
2024
Q3 		$817 Buy
+32
New +$741 ﹤0.01% 2011

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Capital Performance Advisors's ELVN Position: Q4 2024 in Review

Capital Performance Advisors sold out of Enliven Therapeutics (ELVN) in Q4 2024, closing a stake of 32 shares — an estimated $817 sold.

Capital Performance Advisors first reported a position in ELVN in Q3 2024 and held it in 1 quarter. The position peaked at $817 in Q3 2024. 113 funds tracked by Wall St. Rank hold ELVN as of Q4 2024.

  • Capital Performance Advisors reported no remaining Enliven Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 32 Enliven Therapeutics shares in Q4 2024, an estimated $817.
  • Capital Performance Advisors first reported a position in Enliven Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Enliven Therapeutics position peaked at $817 in Q3 2024.
  • 113 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.